8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.

Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G)

Bioeffects Seen

Authors not listed · 2017

Share:

Specific EMF frequencies can enhance chemotherapy effectiveness against aggressive brain cancers, revealing complex biological interactions beyond simple harm.

Plain English Summary

Summary written for general audiences

Researchers tested whether extremely low-frequency electromagnetic fields (100 Hz, 100 Gauss) could enhance the cancer-fighting effects of temozolomide, a chemotherapy drug used for aggressive brain tumors called glioblastoma. They found that combining EMF exposure with the drug significantly increased cancer cell death compared to using either treatment alone. This suggests EMF might help overcome drug resistance in one of the deadliest forms of brain cancer.

Why This Matters

This study reveals a fascinating paradox in EMF research. While we typically focus on EMF's potential health risks, this research demonstrates how specific frequencies and intensities might actually enhance medical treatments. The 100 Hz frequency used here falls within the extremely low-frequency range you encounter from power lines and household wiring, though at much higher intensities (100 Gauss versus typical residential exposures of 1-4 milligauss). What makes this particularly significant is the target: glioblastoma multiforme, which has a median survival of just 15 months and resists most treatments. The researchers found that EMF exposure increased reactive oxygen species and triggered programmed cell death pathways that the cancer drug alone couldn't fully activate. This doesn't mean living near power lines fights cancer, but it does suggest that our understanding of EMF biological effects is far more nuanced than simple harm versus safety. The key lies in frequency, intensity, duration, and biological context.

Exposure Information

A logarithmic frequency spectrum from 10 Hz to 100 GHz showing where this study's 100 Hz exposure sits relative to common EMF sources.Where This Frequency Sits on the EMF SpectrumELFVLFLF / MFHF / VHFUHFSHFmm10 Hz100 GHzThis study: 100 HzCell phones~1 GHzWiFi2.4 GHz5G mm28 GHzLogarithmic scale

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2017). Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).
Show BibTeX
@article{cytotoxicity_of_temozolomide_on_human_glioblastoma_cells_is_enhanced_by_the_concomitant_exposure_to_an_extremely_low_frequency_electromagnetic_field_100hz_100g_ce3950,
  author = {Unknown},
  title = {Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G)},
  year = {2017},
  doi = {10.1016/j.biopha.2017.05.050},
  
}

Quick Questions About This Study

Yes, this study found that 100 Hz EMF at 100 Gauss significantly enhanced temozolomide chemotherapy effectiveness against glioblastoma cells, increasing cancer cell death through enhanced programmed cell death pathways and oxidative stress mechanisms.
The 100 Gauss (10,000 milligauss) EMF used was extremely powerful, roughly 2,500-10,000 times stronger than typical residential EMF exposures from power lines and household appliances, which usually measure 1-4 milligauss in homes.
Yes, the EMF exposure made both U87 and T98G glioblastoma cell lines more sensitive to temozolomide by increasing pro-death proteins (P53, Bax, Caspase-3) while decreasing survival proteins (Bcl-2, Cyclin-D1).
The EMF exposure increased reactive oxygen species production and activated heme oxygenase-1 genes, creating oxidative stress that enhanced the chemotherapy drug's ability to trigger programmed cancer cell death.
The research suggests potential for overcoming temozolomide resistance in glioblastoma, but this was only tested in laboratory cell cultures. Clinical trials would be needed to determine safety and effectiveness in actual patients.